Pacira BioSciences (PCRX) – Investment Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Pacira BioSciences (NASDAQ: PCRX):

• 10/9/2026 – Pacira BioSciences was downgraded by Truist Financial Corporation from “buy” to “hold”. They now have a $36.50 price target on the stock, up from $31.00.
• 10/9/2026 – Pacira BioSciences had its price target raised by Royal Bank Of Canada from $25.00 to $36.50. They now have a “sector perform” rating on the stock.
• 10/9/2026 – Pacira BioSciences was downgraded by HC Wainwright from “buy” to “hold”. They now have a $36.50 price target on the stock, down from $38.00.
• 10/8/2026 – Pacira BioSciences was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 10/8/2026 – Pacira BioSciences was upgraded by JPMorgan Chase & Co. from “underweight” to “neutral”. They now have a $36.50 price target on the stock.
• 10/8/2026 – Pacira BioSciences was downgraded by Jefferies Financial Group Inc. from “buy” to “hold”. They now have a $36.00 price target on the stock.
• 10/8/2026 – Pacira BioSciences was downgraded by Needham & Company LLC from “buy” to “hold”.
• 10/7/2026 – Pacira BioSciences had its price target raised by Truist Financial Corporation from $30.00 to $31.00. They now have a “buy” rating on the stock.
• 10/5/2026 – Pacira BioSciences was downgraded by Zacks Research from “hold” to “strong sell”.
• 9/26/2026 – Pacira BioSciences was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 9/23/2026 – Pacira BioSciences is now covered by Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $32.00 price target on the stock.
• 9/16/2026 – Pacira BioSciences was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 9/9/2026 – Pacira BioSciences is now covered by Leerink Partners. They set a “market perform” rating and a $28.00 price target on the stock.
• 9/1/2026 – Pacira BioSciences was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.

Insider Buying and Selling

In other Pacira BioSciences news, SVP Lauren Riker sold 6,000 shares of the stock in a transaction that occurred on Thursday, October 8th. The shares were sold at an average price of $36.32, for a total transaction of $217,920.00. Following the transaction, the senior vice president directly owned 62,284 shares in the company, valued at $2,262,154.88. This trade represents a 8.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jonathan Slonin sold 3,040 shares of Pacira BioSciences stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $23.23, for a total transaction of $70,619.20. Following the transaction, the insider directly owned 216,384 shares in the company, valued at $5,026,600.32. This trade represents a 1.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.40% of the stock is owned by company insiders.

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain-management and regenerative health solutions. The company’s products are designed to address acute postsurgical pain and osteoarthritis-related pain while supporting efforts to reduce reliance on opioid medications.

Pacira’s lead product is EXPAREL, an extended-release formulation of bupivacaine administered by injection for postsurgical pain management. The company also markets ZILRETTA, an extended-release corticosteroid injection indicated for osteoarthritis knee pain, and iovera°, a cryoanalgesia system that uses controlled cooling to temporarily block peripheral nerves and relieve pain.

Formerly known as Pacira Pharmaceuticals, the company adopted the Pacira BioSciences name to reflect its broader focus on innovative pain and regenerative-health therapies.